Még nem toboroz
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· 3. fázis· Nationwide Children's Hospital· Forrás
Még nem toboroz
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
2024-517295-37-00· 3. fázis· University Of Cologne· Forrás
Még nem toboroz
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
2025-522190-11-01· 3. fázis· Universitaetsklinikum Schleswig-Holstein AöR· Forrás
Még nem toboroz
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
NCT07178730· 3. fázis· Women's Cancer Study Group GmbH· Forrás
Toboroz
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07365241· 3. fázis· AbbVie· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270· 3. fázis· Genmab· Forrás
Toboroz
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Még nem toboroz
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
2025-521908-22-00· 2/3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Toboroz
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· 3. fázis· Pfizer· Forrás
Toboroz
Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma
2022-500676-59-00· 2. fázis· GPOH gGmbH· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· 3. fázis· Pfizer· Forrás
Toboroz
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519· 3. fázis· AbbVie· Forrás
Toboroz
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· 3. fázis· Pfizer· Forrás
Toboroz
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· 3. fázis· BioNTech SE· Forrás
Toboroz
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112· 3. fázis· AstraZeneca· Forrás
Toboroz
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
NCT06571149· 4. fázis· Insel Gruppe AG, University Hospital Bern· Forrás
Toboroz
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
NCT06201234· 2. fázis· GBG Forschungs GmbH· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647· 3. fázis· AstraZeneca· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
NCT06465329· 2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
2023-509340-10-00· 3. fázis· OSE Immunotherapeutics· Forrás
Toboroz
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
NCT06081244· 3. fázis· Women's Cancer Study Group GmbH· Forrás
Fut, nem toboroz
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140· 2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations
2023-503865-48-00· 2. fázis· Taiho Oncology Inc.· Forrás
Fut, nem toboroz
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744· 3. fázis· Genmab· Forrás
Toboroz
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
NCT06061094· 2. fázis· Goethe University· Forrás
Toboroz
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
NCT05665140· 2/3. fázis· University Hopsital Schleswig Holstein Campus Lübeck· Forrás
Fut, nem toboroz
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066· 3. fázis· Genmab· Forrás
Toboroz
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
NCT05009082· 3. fázis· AGO Study Group· Forrás
Fut, nem toboroz
A phase II, open-label, single arm study to evaluate the efficacy of
Luspatercept in Erythropoiesis-stimulating agent naive lower-risk
MDS patients with or without ring sideroblasts who do not require
RBC transfusions
2024-516438-36-00· 2. fázis· Universitaet Leipzig· Forrás
Toboroz
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
2022-501180-40-00· 3. fázis· GPOH gGmbH· Forrás
Toboroz
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
NCT05362760· 4. fázis· Prof. Wolfgang Janni· Forrás
Toboroz
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846· 3. fázis· AbbVie· Forrás
Toboroz
ITP Registry and Accompanying Biospecimen Collection
NCT05152238· Jena University Hospital· Forrás
Contact: Martin Wolf, Prof. Dr.
Toboroz
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
2024-510578-25-00· 3. fázis· The University Of Birmingham· Forrás
Fut, nem toboroz
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)
NCT04602533· 2. fázis· Michael Hopp· Forrás
Toboroz
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596· 2/3. fázis· Mirati Therapeutics Inc.· Forrás
Toboroz
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· 1/2. fázis· University of Birmingham· Forrás
Toboroz
An international trial for children with atypical teratoid/rhabdoid tumours (ATRT)
2022-501456-28-00· 3. fázis· GPOH gGmbH· Forrás
Toboroz
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
2022-501454-11-00· 3. fázis· GPOH gGmbH· Forrás
Toboroz
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494· 3. fázis· University Hospital Muenster· Forrás
Fut, nem toboroz
Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours
2023-507582-25-00· 3. fázis· Rheinische Friedrich-Wilhelms-Universitaet Bonn· Forrás
Toboroz
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
NCT03643276· 3. fázis· Martin Schrappe· Forrás
Toboroz
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
NCT03590171· 2. fázis· Charite University, Berlin, Germany· Forrás
Showing 50 of 57.